BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37351514)

  • 1. Mechanism of sorafenib resistance associated with ferroptosis in HCC.
    Guo L; Hu C; Yao M; Han G
    Front Pharmacol; 2023; 14():1207496. PubMed ID: 37351514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma.
    Li B; Wei S; Yang L; Peng X; Ma Y; Wu B; Fan Q; Yang S; Li X; Jin H; Tang S; Huang M; Li H; Liu J
    Front Oncol; 2021; 11():657723. PubMed ID: 34485112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA CASC11 suppresses sorafenib-triggered ferroptosis via stabilizing SLC7A11 mRNA in hepatocellular carcinoma cells.
    Chen F; Wang L
    Discov Oncol; 2023 Aug; 14(1):145. PubMed ID: 37552314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
    Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
    Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
    Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
    Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing.
    Liu L; Lv Z; Wang M; Zhang D; Liu D; Zhu F
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ferroptosis in hepatocellular carcinoma.
    Nie J; Lin B; Zhou M; Wu L; Zheng T
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2329-2337. PubMed ID: 30167889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma.
    Li X; Yu Q; Zhao R; Guo X; Liu C; Zhang K; Zhang W; Liu J; Yu J; Wang S; Hao Q; Li W; Zhang W; Li M; Zhang Y; Zhang C; Gao Y
    Front Oncol; 2022; 12():898156. PubMed ID: 35814401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
    Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
    Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
    Li X; Li Y; Lian P; Lv Q; Liu F
    Hum Exp Toxicol; 2023; 42():9603271221142818. PubMed ID: 36786348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
    Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
    Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
    Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
    Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy.
    Zhang K; Zhang Q; Jia R; Xiang S; Xu L
    Front Cell Dev Biol; 2023; 11():1156383. PubMed ID: 37181755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
    Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
    Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPLX2 Regulates Ferroptosis and Apoptosis Through NRF2 Pathway in Human Hepatocellular Carcinoma Cells.
    Li H; Zhao J; Zhong XL; Xu PY; Du LJ; Fang P; Tan LJ; Li MJ; Zhang CF; Cao TS
    Appl Biochem Biotechnol; 2023 Jan; 195(1):597-609. PubMed ID: 36107387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
    Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
    J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1α to inhibit apoptosis.
    Gao Z; Wang D; Yang J; Li M; Ling C; Lv D; Cao Y; Chen Z; Shi C; Shen H; Tang Y
    Biomed Pharmacother; 2023 Jul; 163():114750. PubMed ID: 37087978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
    Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
    Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma.
    Kim DH; Kim MJ; Kim NY; Lee S; Byun JK; Yun JW; Lee J; Jin J; Kim J; Chin J; Cho SJ; Lee IK; Choi YK; Park KG
    BMB Rep; 2022 Nov; 55(11):547-552. PubMed ID: 36016501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.